Abstract
Immune Checkpoint Inhibitors (ICIs) have substantially improved survival in patients with advanced malignancies. However, ICIs are associated with a unique spectrum of side effects termed Immune-Related Adverse Events (irAEs). To ensure treatment safety, research efforts are needed to comprehensively detect and understand irAEs from real world data (RWD). The goal of this work is to evaluate a Machine Learning-based phenotyping approach that can identify patients with irAEs from a large volume of retrospective clinical notes representing RWD. Evaluation shows promising results with an average F1-score=0.75 and AUC-ROC=0.78. While the extraction of any available irAEs in charts achieves high accuracy, individual irAEs extraction has room for further improvement.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Grant #1: NCI Cancer Center Support Grant for the Georgetown Lombardi Comprehensive Cancer Center ( P30 CA51008) Initials of the authors who received each award: SM, MBA, NJS Grant numbers awarded to each author: P30 CA51008 The full name of each funder: National Cancer Institute, NIH URL of each funder website: https://grants.nih.gov/grants/guide/pa-files/par-20-043.html The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Grant #2: NHGRI Clinical Genome Resource - Expert Curation and EHR Integration (U41 HG009650) Initials of the authors who received each award: SM, SG, AB Grant numbers awarded to each author: U41 HG009650 The full name of each funder: National Human Genome Research Institute, NIH URL of each funder website: https://www.genome.gov/Funded-Programs-Projects/ClinGen-Clinical-Genome-Resource The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The parent study was conducted under an IRB study #2017-0559 approved by Georgetown University review board. The current project used a de-identified dataset from the registry and didn't require an IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos